In the upcoming Year of the Loong, prosperity is anticipated, as the Dragon spreads its wings. Evopoint Biosciences Co., Ltd. (hereinafter referred ...
More
Evopoint Biosciences announced that its partner Everest Medicines (HKEX 1952.HK) has reported positive results in Preliminary Analysis of Phase 1b/2...
More
On September 10, 2024, Evopoint Biosciences Co., Ltd. was informed by CDE of NMPA that the EZH2 inhibitor XNW5004 has officially been designated as ...
More
On June 14, 2024, XNW27011, a new-generation Antibody-Coupled Drug (ADC) developed by Evopoint, has been granted Fast Track Designation (FTD) status...
More
On February 8, 2024, Evopoint Biosciences Co., Ltd. (hereinafter referred to as “Evopoint”) announced that the first patient had been enrolled in th...
More
Follow us
